H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - ca.investing.com

33% confirmed PSA50 response rate for ORIC’s rinzimetostat + Nubeqa in an 18-patient cohort, with radiographic PFS of 93%/84%/84% at the 3/4/5-month time points; H.C. Wainwright reiterated a Buy and $25 price target while the stock trades at $7.48. ORIC plans a global Phase 3 Himalayas-1 (~600 patients, >20 countries) to start H1 2026, with Phase 1b rinzimetostat data due March 31, 2026; the company reports a strong balance sheet (current ratio 14.13, cash > debt) and is flagged as undervalued by InvestingPro.

Analysis

ORIC’s pathway to a registrational win creates concentrated idiosyncratic upside that is not fully correlated with broad biotech beta; the structural value here is in a binary program de-risking window rather than gradual revenue inflection. Because a rival program from a deep-pocketed incumbent is already further along, any positive mid-stage signal for ORIC will be measured against a moving benchmark — meaning market upside hinges less on absolute efficacy and more on differentiators (safety, tolerability, durability, ease of combo dosing) that affect label breadth and commercial positioning.

Second-order winners include niche contract research organizations and diagnostics vendors that supply specialized imaging and PSA-assay endpoints since faster enrollment and cleaner endpoints reduce trial cost per patient and improve sponsor economics. Conversely, small biotechs with single-program risk may see funding pressure if ORIC’s readout narrows the number of viable combo-therapy pathways, compressing investor appetite for crowded MoA approaches.

Tail risks are classic binary-event exposures: an unexpected safety signal or cross-trial comparability failure can erase implied upside quickly; regulatory and payer acceptance depends on demonstrated patient-level benefit beyond surrogate endpoints, which can take multiple years to settle. Time your exposure around discrete catalyst windows (near-term efficacy/safety updates and subsequent registrational enrollment milestones); expect volatility mean reversion within 1–3 months of any incremental readout and potential M&A chatter to compress premia inside a 6–12 month horizon.

Key Decisions for Investors

• Directional defined-risk long: Buy ORIC 6–9 month call spread sized to 0.25% of fund NAV (buy a 25–35% OTM call, sell a 70–85% OTM call). Rationale: caps premium spend while capturing >3x upside if the program clears near-term catalysts; exit on any confirmed safety signal or if implied vol falls >40% post-readout.
• Hedge-protected equity: Acquire ORIC stock (size 0.5% NAV) and buy 6–9 month puts ~20% OTM equal to 30% of position notional. Rationale: retains upside to a positive regulatory narrative while limiting downside to ~20–30% net in a negative binary outcome; reassess hedge after the next efficacy update.
• Idiosyncratic alpha pair: Long ORIC (0.5% NAV) / Short an equal-dollar basket of 4 small-cap oncology peers (total 0.5% NAV) for 6–12 months. Rationale: isolates program-specific upside vs sector beta; take profits if ORIC’s implied outperformance exceeds 50% vs the basket or if competitor Phase 3 clears the same label.
• Event-volatility play (opportunistic): If implied vol spikes >60% pre-catalyst, sell a near-term strangle sized to 0.2% NAV against the long-call-spread above to monetize mean reversion, but maintain cash reserves for rapid deleveraging on adverse outcomes. Risk: tail losses if the readout surprises materially; hard stop at a 30% loss on premium.